Table 1 Inhibition (%) of protease activity by actively and non-actively transcribed cystatins during nodule life-span
Cystatin | Cathepsin L-like activity | Cathepsin B-like activity | ||||||
|---|---|---|---|---|---|---|---|---|
(% inhibition) | (% inhibition) | |||||||
|  | 4 weeks | 8 weeks | 14 weeks | p ≤ 0.05 | 4 weeks | 8 weeks | 14 weeks | p ≤ 0.05 |
Positive control (E64) | 50.3 ± 1.1 | 26.4 ± 5.0 | 31.9 ± 4.5 | *ac | 37.2 ± 2.3 | NI | NI | *ac |
OCI (1 μM) | 47.4 ± 1.3 | 28.2 ± 2.3 | 22.7 ± 7.3 | *ac | 44.9 ± 3.8 | NI | NI | *ac |
Actively transcribed | ||||||||
Glyma05g28250 | 36.1 ± 0.5 | 31.5 ± 0.9 | 30.6 ± 0.4 | ns | 32.8 ± 1.4 | 32.8 ± 1.4 | NI | *bc |
Glyma13g04250 | 26.4 ± 0.9 | NI | 29.7 ± 1.8 | *ab | 27.6 ± 2.3 | 27.6 ± 2.3 | 24.9 ± 3.2 | *ab |
Glyma13g27980 | 33.2 ± 2.3 | NI | NI | *ac | 42.0 ± 0.2 | 42.0 ± 0.2 | NI | *ac |
Glyma14g04250 | NI | NI | 21.9 ± 1.6 | *bc | NI | NI | NI | ns |
Glyma15g36180 | 49.9 ± 5.3 | 28.4 ± 3.1 | NI | *abc | 48.7 ± 4.5 | 48.7 ± 4.5 | NI | *ac |
Glyma20g08800 | NI | NI | NI | ns | NI | NI | 32.5 ± 3.2 | *ab |
Non-actively transcribed | ||||||||
Glyma04g10360 | 38.6 ± 2.9 | 32.0 ± 3.9 | 39.0 ± 3.5 | ns | 35.3 ± 5.5 | 30.9 ± 5.5 | 28.6 ± 5.8 | ns |
Glyma07g39590 | 47.5 ± 3.2 | 39.1 ± 9.5 | 51.3 ± 5.1 | *b | 42.3 ± 5.3 | 26.9 ± 8.7 | 34.0 ± 2.9 | *a |
Glyma08g11210 | 43.6 ± 3.8 | 28.2 ± 1.8 | 33.5 ± 4.3 | *abc | 42.1 ± 4.4 | NI | NI | *ac |
Glyma14g04260 | 58.9 ± 1.1 | 37.8 ± 4.9 | 36.2 ± 3.3 | *ac | 46.4 ± 1.8 | NI | NI | *ac |
(1st domain) | Â | Â | Â | Â | Â | Â | Â | Â |
Glyma14g04260 | 36.6 ± 4.9 | NI | NI | *ac | 39.8 ± 5.6 | NI | NI | *ac |
(2nd domain) | Â | Â | Â | Â | Â | Â | Â | Â |
Glyma14g04291 | 42.1 ± 3.3 | NI | NI | *ac | 30.9 ± 5.6 | NI | NI | *ac |
(1st domain) | Â | Â | Â | Â | Â | Â | Â | Â |
Glyma14g04291 | 40.8 ± 8.3 | NI | NI | *ac | 28.6 ± 8.4 | NI | NI | *ac |
(2nd domain) | Â | Â | Â | Â | Â | Â | Â | Â |
Glama18g12240 | 54.0 ± 2.6 | 43.1 ± 1.9 | 51.5 ± 3.7 | *a | 36.6 ± 5.8 | 28.3 ± 3.9 | 22.4 ± 7.4 | *c |